Discover how cfDNA fragmentome tests could help detect liver disease early and track health. Learn more about this emerging ...
New data supports GraftAssure commercialization efforts Multi-center study featured 249 biopsy-matched patients Proprietary “Combination Model” ...
A DNA screening to look for fetal abnormalities can render some unexpected results. According to a new analysis, a cell-free DNA screening to test for chromosomal disorders can also reveal undetected ...
Study shows iMDx test equivalent to NGS kits for dd-cfDNA measurement in kidney transplant patients, supporting future commercialization efforts. Results from a head-to-head comparison show iMDx's ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the American Journal of Transplantation (AJT) ...
Validation study published in the Journal of the American Society of Nephrology (JASN) showed improved sensitivity with quantification vs. dd-cfDNA fraction alone AUSTIN, Texas, Sept. 9, 2021 ...
AUSTIN, Texas, Oct. 4, 2022 /PRNewswire/ -- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of the latest data from the Trifecta ...
Gestational diabetes mellitus (GDM) is a prevalent pregnancy complication posing significant health risks to both mothers and their newborns. Early detection and treatment of GDM are crucial to ...
In 2013, researchers reported an eye-opening case of a healthy pregnant woman with a puzzling prenatal test result. A routine genetic screen using cell-free DNA—a highly accurate blood test—suggested ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results